Play­ing catch-up, Eli Lil­ly is hus­tling pos­i­tive PhI­II CGRP mi­graine da­ta to the FDA as late-stage ri­val­ry heats up

Eli Lil­ly is hus­tling up a bi­o­log­ics ap­pli­ca­tion for its close­ly-watched mi­graine drug gal­canezum­ab af­ter post­ing some re­mark­ably con­sis­tent and pos­i­tive late-stage da­ta from three Phase III stud­ies.

The top-line da­ta from the Lil­ly $LLY study demon­strat­ed that the 120 and 240 mg dos­es re­duced the av­er­age num­ber of mi­graine days by 4.3 to 4.8 days and 4.2 to 4.6 days a month. The place­bo arm had a 2.3 to 2.8 day month­ly drop in mi­graine days, on av­er­age, leav­ing the drug with a con­sis­tent two-day ad­van­tage that will like­ly do fair­ly well in the mar­ket­ing bat­tle to come as Te­va, Alder and the pow­er­house duo of No­var­tis $NVS and Am­gen $AMGN hus­tle their com­pet­ing CGRP drugs to the mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER